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Two interesting therapeutic proposals for cancer treatment emerged at the beginning of the 21st 
century. The first one was metronomic chemotherapy, which refers to the chronic 
administration of chemotherapeutic agents, in low doses, without extended drug-free periods. 
Then, the idea of drug repositioning in oncology, the use of well-known drugs that were created 
for other uses to be utilized in oncology, gained strength. Shortly after, the two strategies were 
merged in one, named metronomics.  Both approaches share several features which make 
metronomics an appealing choice for cancer treatment: use of known and approved drugs, thus 
diminishing the time necessary to enter to the clinic, therapeutic effect, low toxicity, oral 
administration, better life quality, low costs because of the use of, generally, out of patent drugs, 
possibility of use, even in countries with very low economic resources. 
Many chemotherapy and repurposed drugs were tested with metronomics approaches for the 
treatment of mammary cancer, the most common malignancy in women worldwide, leading to 
high rates of mortality. The wide range of therapeutic models studied, paralleled the wide range 
of responses obtained, like tumor growth and metastasis inhibition, overall survival increase, 
lack of toxicity, better life quality, among others. The accomplishments reached, and the 
challenges faced by researchers, are discussed.  
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Breast cancer is the most frequently diagnosed cancer and the most common cause of cancer 
death among women in the world. GLOBOCAN has estimated for 2018 an incidence of 24.2% 
and 15% of mortality caused by cancer in women worldwide [1]. According to the latest 
statistics, only in USA for 2019, are expected 268,600 new cases of invasive breast cancer and 
41,760 deaths from breast cancer [2]. In Argentina, it represents the cancer with the highest 
incidence in women with a rate of 73 new cases per 100.000 inhabitants [3]. 
The improvement of breast cancer treatments which involve surgery, chemotherapy, 
radiotherapy, hormone therapy, targeted therapies and, more recently, the addition of 
immunotherapy. Those treatments has increased the 5 years’ survival rates up to 99% for 
localized cancer but it is still very low (27%) for metastatic disease [4]. The treatment of cancer 
patients at later stages is more difficult and challenging, leading both to poor clinical results 
and to a significant decrease in patient´s quality of life (QoL). 
Standard chemotherapy treatments rely on the administration of doses of drugs near the 
maximum tolerated dose (MTD). They cause tumor cell death, but also, mild to severe 
toxicities. This kind of schedule is typically administered every 3 weeks, with a long drug-free 
period that allows patient’s recovery from the adverse effects of chemotherapy. Unfortunately, 
the rest period also allows the regrowth of cancer cells, eventually also selecting more 
aggressive and/or resistant clones [5]. The conventional regimens have several drawbacks 
namely, the acquired resistance against the administered compounds, the frequent toxicities 
induced by them, with the consequence of QoL deterioration. Last but not least, the high costs 
of novel treatments are limiting the access to them in healthcare systems worldwide, and it has 
been a topic of discussion in many countries, not only in low and middle income, but also, in 




Those disadvantages fueled the search for effective treatments. This search entails three goals 
that are equally important, at least from our point of view, namely: i) therapeutic efficacy; ii) 
good QoL for the patients, an aspect somehow neglected up to now, and to which researchers 
are giving more importance; importantly, this goal implies the improvement of therapeutic 
compliance;  and, last but not least, iii) economic viability, that is to say, ensuring that all the 
patients have access to treatment, a situation that is not the case at present in several low and 
middle income countries (LMIC). 
Two interesting therapeutic proposals, posing different approaches for the treatment of 
malignant tumors, emerged during the 21st century.  
The first one was metronomic chemotherapy (MCT), a term coined by D. Hanahan [6] which 
refers to the chronic administration of chemotherapeutic agents, in low doses, without extended 
rest periods. The foundational papers of J. Folkman [7] and R. Kerbel [8] groups, set the bases 
of this treatment modality. From then on, many other researchers contributed with their 
investigations to increase the knowledge about mechanisms of action, therapeutic effects for 
different tumor types in different experimental models and, drugs suitable for their use in MCT 
schedules both, for individual or combined treatments. Several reviews have comprehensively 
summarized that work [9; 10; 11; 12, 13; 14; 15; 16]. Nowadays, MCT is considered a valid 
alternative for patients who progressed to several lines of chemotherapy [17] and, importantly, 
for pediatric cancer in LMIC [18]. 
The therapeutic effect of MCT is achieved through its antiangiogenic action, mainly targeting 
the activated tumor blood vessels, which are permanently inhibited by the chronic 
administration of low doses of drugs. In contrast, standard chemotherapy, in spite of inhibiting 
the proliferation of tumor endothelial cells, cannot maintain this effect, because of the extended 




circulating endothelial cells (CECs) but also endothelial progenitor cells (CEPs) [19; 20; 21], 
modulates pro- and/or antiangiogenic molecules like vascular endothelial growth factor 
(VEGF) [9; 22; 23; 24], soluble VEGF receptor 2 (sVEGFR-2) [245; 254; 26], thrombospondin-
1(TSP-1) [27; 28], among others. Another important mechanism of action of MCT consists in 
the restoration of the antitumor immune response [10; 29], through the inhibition of T 
regulatory cells [30; 31] and mieloid-derived suppressor cells [32] and the stimulation of 
dendritic cells [33]. The inhibition of cancer stem cells (CSCs) has also been described as a 
probable mechanism. Kerbel et al found that metronomic cyclophosphamide inhibited sphere 
forming of C6 rat glioma CSCs. Also, it has been suggested that the inhibition of tumor 
vasculature disrupts CSCs, thus antiangiogenic therapy could also inhibit CSCs. [34]. Also, the 
induction of tumor dormancy [16] or, even, a direct antitumor effect [10;35], have been 
proposed as responsible, at least in part, of the therapeutic effect of MCT (Fig. 1) 
Several years after the beginning of MCT research, the idea of drug repositioning in oncology, 
the use of well-known and characterized drugs that were created for other uses to be utilized in 
oncology, gained strength [36; 37]. This is an interesting approach that points to widen the 
repertoire of therapeutic resources without need of new pharmacologic developments but 
employing the ones that are already able to be used. The advance in the knowledge of 
relationships between chemical structure and biologic activity and in the effect of different 
compounds on gene expression and on metabolic and signaling pathways, made it possible to 
predict that many old drugs could be useful for cancer treatment. That proposal is drawing the 
attention of many oncologist, mainly because of the already known pharmacokinetics, 
pharmacodynamics and toxicities profiles, a fact that significantly diminish the time necessary 
to translate it to the clinic. 
Shortly after, the two strategies, metronomic chemotherapy and drug repositioning, were 




Both approaches share several features which make metronomics an appealing choice for cancer 
treatment: use of known and approved drugs, thus diminishing the time necessary to enter to 
the clinic, therapeutic effect, low toxicity, oral administration, better quality of life, low costs 
because of the use of, generally, out of patent drugs and last but not least, possibility of use 
even in countries with very low economic resources.  
Here, we shall summarize the main findings, both in the preclinical and the clinical setting, in 





2. PRE-CLINICAL SETTING 
Shortly after the launching of MCT research, with the first two published papers [7; 8], different 
experimental models were developed in order to study the effect of drugs administered with a 
MCT schedule for the treatment of breast cancer.  
The use of single drugs in MCT for experimental breast cancer has been scarce. 
Cyclophosphamide (CY), an alkylating agent that has been used for more than 60 years for 
standard chemotherapy treatment, can also be used in a metronomic regimen, and it was the 
first drug to be used as monotherapy with a metronomic schedule. The combination of 
metronomic daily oral low dose CY with intermittent bolus-dose CY every 3 or 6 weeks, 
improved the therapeutic effect, delaying tumor progression with very mild toxicity and 
reduction of circulating endothelial progenitor cells [39]. Moreover, MCT with Paclitaxel 
(PTX) showed a higher inhibition of primary and metastatic breast tumors and lower toxicity 
than those obtained with MTD therapy, with decrease of angiogenesis and lymphangiogenesis 
[40].  
Apart from those experiences with single drugs, most of the researchers investigating MCT 
used, from the very beginning, different combinations of drugs, looking for good therapeutic 
results. Cyclophosphamide administered continuously in the drinking water with an 
antiangiogenic drug, DC101 in mice carrying tumors derived from human breast cell lines, 
showed a significant antitumor efficacy, proved to be safe, with a moderate grade of efficacy, 
and potentially applicable to chronic treatment [41]. Klement et al obtained a significant and 
lasting antitumor effect using a combination of low-dose/metronomic Taxol, Vinblastine, or 




The effect of metronomic CY was evaluated not only as monotherapy but also in combination 
with many different agents. The combination of metronomic low dose CY and weekly 
Tirapazamine, an agent that exerts a selective cytotoxicity for hypoxic tumor cells, enhanced 
the antitumor effect [43]. The use of combined CY and UFT, a 4:1 molar combination of Uracil 
and Tegafur, showed an antimetastatic effect, in the absence of effect on localized primary 
tumors [44]. Vascular disrupting agents (VDA) target established abnormal vasculature by 
binding to endothelial cells-associated tubulin. The combination of VDA OXI-4503 with a 
classic CY MCT showed better antitumor effect than that obtained with the mono treatments. 
OXI-4503 was administrated i.p. after 6 days of treatment with CY. The therapeutic effect, 
achieved without toxicity, consisted of diminished microvessel density and proliferation rates, 
together with increased tumor hypoxia and cell apoptosis [45]. Francia et al demonstrated that 
Trastuzumab combined with metronomic low-dose CY is effective in models of highly 
aggressive Her-2+ spontaneously metastatic human breast cancer. The authors found a 
prolongation in survival and minimal toxicity with the combined therapy [46]. The oral prodrug 
of Gemcitabine (GEM), LY2334737, instead of GEM, that is administered i.p, achieved anti-
tumor effect alone or in combination with CY in a metronomic schedule. LY2334737 did not 
suppress circulating endothelial progenitor cells but increased vessel stability and functionality 
and caused higher blood flow [35]. We demonstrated the antitumor and antimetastatic effect of 
the combination of metronomic CY with Celecoxib (CEL), a cyclooxygenase 2 inhibitor, in 
two triple negative murine mammary tumor models [47]. Utilizing the same models, we 
combined MCT with CY and Doxorubicin (DOX) with similar results [48]. In both studies the 
therapeutic effect was achieved without toxicity. Together with a decrease of proliferation and 
an increase of apoptosis of the tumor cells, there was a diminution in VEGF serum levels, 




A novel therapeutic approach was the combination of metronomic CY with USMB (ultrasound 
stimulated microbubbles) [49]. In this study, the combination showed significant reduced tumor 
growth rates and higher survival than that obtained with the individual treatments in a TNBC 
murine model. The therapeutic schedule combining low dose metronomic CY and Capecitabine 
(CAP) also produced antitumor and antimetastatic effects [50].  
The appearance and use of immune checkpoint inhibitors in the treatment of several types of 
cancer [51] led to the assumption that combining its administration with MCT would have a 
synergistic effect on the antitumor immune response, increasing the therapeutic efficacy. Parra 
demonstrated that anti-CTLA-4 therapy together with metronomic CY, or the antibody 
followed by sequential therapy with GEM reduced tumor growth. However, in some cases there 
were relapses and the appearance of metastases [52].  
Another attractive therapeutic approach is related to the use of enzyme prodrug systems, which 
are able to minimize systemic toxicity. The administration of CY at low doses, combined with 
a Tumor Vasculature-targeted Enzyme Prodrug System and Rapamycin, acted synergistically 
decreasing tumor volumes, increasing survival and diminishing the number of lung metastatic 
nodules [53].  
Recently, we found that MCT with CY plus Losartan, an angiotensin II receptor antagonist, is 
a successful drug combination that, interestingly, caused % 60 of complete regressions in a very 
aggressive murine model of TNBC [54]. We also shed some light into the mechanisms 
implicated in its antitumor effect, mainly pointing to different elements of the tumor 
microenvironment like angiogenic factors, immune cells and cancer associated fibroblasts, with 
the indirect/direct consequence of tumor cells impairment. Recently, Orecchioni studied the 
antitumor and antimetastatic effects of Vinorelbine (VRB), CY and 5-FU, three orally active 




a TNBC model. The authors studied the combination of the different drugs with checkpoint 
inhibitors anti-PD-1 and anti-PD-L1, a kind of antibodies that are active in many types of 
cancers. They showed that the drugs had a synergic effect with anti-PD-L1 [55].  
Doxorubicin is one of the drugs that are frequently used in the treatment of breast cancer. It was 
evaluated the in vivo antitumor effect of metronomic low-dose oral DOX combined with Chk1 
(Checkpoint kinase 1) inhibitor MK-8776. The abrogation of the Chk1 checkpoint could 
selectively exert lethality with low-concentration DOX, against p53-deficient breast cancer by 
forcing the cells to accumulate Doxorubicin-induced DNA damage. The animal studies showed 
that MK-8776 improved the cytotoxic activity of MCT with DOX against p53-deficient cancer 
cells, without showing systemic toxicity [56]. Also, in vivo and in vitro assays demonstrated 
that Methylglyoxal, a glycolytic metabolite, produced a synergic effect in the cytotoxicity 
mediated by DOX and Cisplatin in MDA MB 231 and MCF cell lines. The combined treatment 
inhibited mammosphere formation, eliminating cancer stem as well as non-stem cancer cells. 
[57].  
Other combinations of agents were studied with a MCT schedule in preclinical model, as well. 
Zhang and colleagues developed an effective therapeutic scheme, combining the use of CAP in 
a metronomic scheme with Ginsenoside Rg3, the active ingredient in ginseng extract. This 
combination was shown to have antiangiogenic effect, low toxicity and lower susceptibility to 
drug resistance [58]. Moreover, Foy studied the combination of peptide mimics with low dose 
chemotherapy. They obtained antitumor effect combining low-dose PTX with either HER-2 or 
VEGF peptide mimics. Those results were obtained with little or null cardiotoxicity [59].  
The treatment that combined Sunitinib with oral Topotecan showed antitumor activity on 
MDA-MB-231/LM2.4 tumors, with an increase in survival. Those effects were not observed 




Srivastava used an adjuvant scheme in a breast cancer model in which they combined anti-
AnG2 antibody, anti-VEGF antibody and MCT with GEM. They obtained a significant 
reduction in metastatic growth [61]. The therapeutic effect of combining Camellia sinensis 
water extract and metronomic Zoledronate was investigated by Luo et al. The authors showed 
significant antitumor effect and proved that the combined treatment decreased lung and liver 
metastasis compared to the individual treatments [62].  
The combination of metronomic Topotecan and Pazopanib, an antiangiogenic tyrosine kinase 
inhibitor, significantly enhanced antitumor activity compared to monotherapy with both drugs 
and prolonged survival, even in the advanced metastatic survival setting. These drugs 
combination showed a marked decrease in tumor vascularity and proliferative index and, also, 
induction of apoptosis [63].  
Other researchers have explored different combinations with some interesting results. Ko and 
colleagues showed that the combination of metronomic Zoledronic acid plus an aqueous extract 
of Coriolus versicolor, an immunomodulatory agent, diminished tumor growth and metastasis 
appearance, in an intratibial breast tumor model [64].  
We also studied the efficacy of a combination of Metformin and Propranolol, two repurposed 
drugs, in TNBC murine models. In vitro studies showed inhibition of proliferation, 
mitochondrial activity, migration and invasion. The drugs combination, tested in vivo, 
significantly decreased tumor growth and prevented metastasis in two TNBC murine models 
[65]. 




The above mentioned preclinical studies gave evidence of therapeutic effect together with 
low toxicity profiles of MCT for breast cancer treatment and, in several cases, paved the 




3. CLINICAL SETTING 
Since its conception, several trials have been published about the activity and safety of 
metronomic chemotherapy in the treatment of breast cancer. Most of the patients included in 
those clinical trials had advanced, multiple metastasized, heavily pretreated tumors, which 
developed progressive disease after standard chemotherapy. However, there are also some 
evidence of activity in locally advanced and neoadjuvant settings. The most common 
chemotherapy agents used in those metronomic schemes were CY, Methotrexate (MTX) and 
CAP, accompanied, or not, with some other hormonal or biological targeted agents. 
 
3.1 METRONOMIC CHEMOTHERAPY IN THE NEOADJUVANT SETTING OF LOCALLY ADVANCED 
BREAST CANCER (LABC) TREATMENT 
It is well known that after several lines of chemotherapy, the chances of response decrease 
significantly line after line. There are not many trials using MCT in the neoadyuvant setting for 
women with LABC. The gold standard for patients with LABC with positive hormone receptors 
are the antagonists of the estrogen receptor, like Tamoxifen, or the non-steroidal aromatase 
inhibitor Letrozole (LET). This is also the case for elderly patients, when chemotherapy is not 
allowed. A randomized phase II trial conducted by Bottini et al. [66] using aromatase inhibitor 
LET and LET plus metronomic CY, 50mg p.o. daily, showed a response rate of 88%; 
unfortunately, the study was not designed to compare response between arms, and both (LET 
and LET+CY) demonstrated to be effective. However, the comparison of both arms suggested 
that the addition of CY increased the activity of LET, explaining the higher response rate in 
that arm. Two pathological complete responses (CR) were observed in both arms, but the 
addition of metronomic CY did not seem to increase the CR rate. Dellapasqua [67] designed a 




metronomic CY in patients who were not suitable to receive a standard chemotherapeutic 
treatment due to age or co-morbidities. The response rate (RR) was 62.1%, but no complete 
responses were observed. The treatment was well tolerated but, unfortunately, showed a limited 
activity in the neo-adjuvant setting. Cancello et al, showed that metronomic CY plus weekly 
PTX after epidoxorubicin-cisplatin-fuorouracil (ECF) as neoadjuvant treatment decreased Ki-
67 and a high proportion of patients had complete pathological response [68]. A small trial 
examined the feasibility of neoadjuvant metronomic chemotherapy in two cohorts, HER2+ and 
HER2− locally advanced BC patients; this trial was negative and it was discontinued due 
toxicity related to treatment [69]. In Table 2 are summarized the main findings of the cited 
clinical trials.  
 
3.2 METRONOMIC CHEMOTHERAPY IN THE METASTATIC SETTING OF BREAST CANCER 
TREATMENT 
 
3.2.1 Metronomic Cyclophosphamide plus Methotrexate and other agents in metastatic 
breast cancer  
As previously said, CY is one of the most widely investigated drug in different metronomic 
schemes. The metronomic dose used in several clinical trials has been set up empirically in 50 
mg p.o. daily [22]. Indeed, the combination of CY+MTX (Methotrexate), was the first 
metronomic chemotherapy protocol reported in the clinic in breast cancer patients by Colleoni 
[22] in 2002; their results stimulated the development of subsequent studies by others. They 
found a response ratio of near 20% with low and manageable toxicity. The addition of 
Thalidomide (TH) to the metronomic protocol, did not improve the RR [23]   in another study 
conducted by the same author. A RR of 50% and clinical benefit of 61% were obtained by 




and CB (17% and 31 %, respectively), in salvage therapy context [71]. On the contrary, Gebbia 
et al. studying the effect of adding MTX to metronomic CY, did not find statistically significant 
differences between cohorts [72]. The addition of biological agents like Trastuzumab (TZB) or 
Bevacizumab (BEV) might also add a synergic antiangiogenic effect in HER2-positive patients, 
leading to a higher CB [73; 74]. Many others tried to get similar results in small trials using this 
scheme alone or combined with other anti-cancer agents like the VEGFR inhibitor Vandetanib 
(VAN) [75], Fulvestrant [76], non-anticancer drugs like TH [23], Dalteparin and Prednisone 
[77] or Idiotype vaccine [787], however outcomes showed non-significant therapeutic 
improvements.  
3.2.2 Metronomic Capecitabine, and derivatives, in Metastatic Breast Cancer  
Oral CAP allows the treatment of breast cancer, simulating the effect of continuous infusion of 
5-FU, with the advantage of its oral administration. The efficacy of CAP as monotherapy has 
been well established for metastatic breast cancer resistant to both, taxanes and anthracyclines. 
The metronomic dose of CAP has not been established, and ranges from 1000 to 1500 mg (500 
mg p.o. three times/day), depending if it is given alone or combined with other agents. 
Metronomic CAP, as single agent therapy, demonstrated to be very effective with a RR of 24% 
in heavily pretreated MBC [79]. These outcomes vary from 21% to 30% with the addition of 
CY [80; 81] or Fulvestrant [82]. Interestingly, the addition of CY and BEV allowed obtaining 
an even better RR of 48% and CB of 68% [83]. A Phase II Trial conducted by Montagna and 
colleagues, designed to study the safety and the RR of a 4 drug combination including CAP + 
CY + ERL + BEV [21] reached a RR of 62% and 75% of CB, with moderate toxicity. In spite 
of these results, the addition of biological agents, like BEV, to standard metronomic CAP is 




Other agents like VRB + CAP, demonstrated activity [85; 86]. Also, Docetaxel (DTX) has been 
added to CAP in patients with prior anthracycline exposure; metastatic breast cancer patients 
showed a RR of 34% and a CB of 42% [87] with this metronomic treatment. Other prodrugs 
from the family of Fluoropyrimidine, like TS-1, showed a RR of 47% and a high disease control 
rate (CB) of 97% in combination with Irinotecan [88].  
3.2.3 Other schemes of metronomic treatment in advanced breast cancer 
Many other schemes of MC have been tested. They include DTX [89]; a 5-drug combination 
involving non-pegylated liposomal doxorubicin (NPLD) [90]; CY+MA (Megestrol acetate) 
[91]; VRB [92]; CY + CEL [24] ; and PLD [93]. Interestingly, Addeo et al. found a 52% RR 
and 77% CB in the treatment of brain metastases with concurrent low dose Temozolomide 
(TMZ) + metronomic oral VRB, and whole-brain radiotherapy in women with advanced breast 
cancer with previously untreated brain metastasis [94]. The highest OS was obtained in a large 
trial using DTX + TZM (27.7 months) [89], followed by the scheme with a 5-drug combination 
(21 months) [90] and PLD (18.35 months) [93]. Several authors described the activity of 
empirical low doses of oral etoposide in breast cancer [95]. In a phase II trial it was 
demonstrated the activity of chronic etoposide in MBC with an ORR of 35% and PR of 21% 
[96]. Also, the most recent multicenter phase II trial of oral etoposide showed a CB of 21.3% 
with a median PFS of 4.5 months [97]. 
Some metronomic schemes have also been evaluated as maintenance therapy in TNBC patients. 
Nasr KE et al developed a large clinical trial using maintenance metronomic after adjuvant FEC 
(Fluorouracil-Epirubicin-CY) and DTX and a control group without maintenance; the study 
arm showed that DFS and OS were 28 and 37 months, respectively, compared to that of control 
groups of 24 and 29 months [98]. The treatment schemes, endpoints and main outcomes of the 




4. CHALLENGES AND FUTURE DIRECTIONS  
In order to establish this proposal as a therapeutic tool among those included in the standard of 
care for breast cancer, several issues are yet to be solved. The experience obtained up to now, 
with advanced breast cancer patients, allow us to conclude that MCT is an active and safe 
therapeutic modality but, in many cases, still empirical. Having the answers to those issues will 
enable to design optimal metronomic chemotherapy schemes with improved outcomes (Fig. 2).   
We should know the best drug candidates, a quality that implies not only clinical effectiveness 
but also low toxicity, possibility of oral administration, known mechanisms of action and low 
cost. Also, there is the need to identify the best drug, or drugs combination, or drugs combined 
with other targeted or non-targeted agents, for each tumor or histologic type.  
Another important issue to be solved is the determination of the optimal biological dose (OBD) 
for each agent and the intervals of administration needed to reach it. Shaked [99], working with 
preclinical tumor models, proposed the use of CEPs as biomarker to determine the OBD in 
MCT treatments. Bocci and Kerbel called the attention on the lack of well-established 
pharmacokinetic profiles and considered it the main obstacle for proposing MCT treatments 
[100]. 
It is also necessary to have data about the best clinical setting, be it neo-adjuvant, adjuvant or 
maintenance, for using metronomics in each clinical case. Moreover, we need to establish the 
suitability of interpolating this therapeutic modality with other treatment approaches, for which 
different clinical trials should be proposed and developed. For instance, one possibility, among 
several, could be reducing the tumor mass with standard chemotherapy and then continuing 
with metronomics. 
Although the generation of resistance to MCT was initially thought to be significantly lower 




albeit by different mechanisms [101]. Different strategies to solve this problem were studied in 
preclinical and clinical models using thrombospondin 1 peptide ABT-510, VEGF pathway 
inhibitors, AKT inhibitor V, autophagy inducer rapamycin, autophagy inhibitor 
hydroxychloroquine and the tumor stroma modulating agents rofecoxib and pioglitazone. These 
therapeutic combinations may represent promising approaches to amplify MCT efficacy [102]. 
Hence, much knowledge is needed about which drugs combination/schemes induce less 
resistance. 
Another important issue to be addressed is the patient selection. The identification of 
biomarkers, particularly the predictive ones, which can significantly point out the patients that 
will respond to the treatment, is still very scarce. Linked to this subject it is the method by 
which, the efficacy of the therapy that determines when to stop MCT, is assessed. Indeed, 
response criteria should be reviewed, because the Response Evaluation Criteria in Solid Tumors 
(RESIST) or WHO criteria, which are designed to detect early effects of cytotoxic 
chemotherapy, may not provide a complete assessment of response in metronomic based 
therapies [103]. Also, the use of metronomics in those scenarios of bad performance status, 
increases the chances of not having good therapeutic results. 
Phase III trials for breast cancer treatment with metronomics must be developed, in order to 
solve many of the unanswered questions. There are scarce examples of Phase III clinical 
protocols [104, 105]. Consequently, based in the previous considerations, large multi-centered 
clinical studies are needed to validate the best selection of the metronomics treatment.  
Another important need is to increase the information about the benefits of the metronomic 
therapeutic approach in specialized media, changing from traditional to modern communication 
media. Most of the time it is mainly used for palliative care, even when the evidence showed 




Last but not least, it is relevant to know in detail the costs of each therapeutic scheme, in order 
to choose those suitable for each country situation. As it is already known, standard 
chemotherapy implies high expenses, not only because of the costs of the drugs patented 
administered, but also due to the need of intravenous administration, which implies 
hospitalization, specialized personnel and disposable items. Also, the costs of counteracting the 
adverse effects of the treatments should be added. On the other hand, MCT generally uses 
generic drugs in oral formulations, with low toxicity, thus avoiding all the related expenses. 
Therefore, the convenience of its use in countries with limited medical resources is crystal clear. 
Moreover, André and colleagues [38] proposed the combination of metronomics with new 
business models in order to make easier and more affordable and efficient the treatment of 
cancer in LMIC and, simultaneously, to favor the research in this area. So, further efforts should 
be done to fulfill those needs.  
 
Ten international experts, in a report describing the current status of the treatment of advanced 
breast cancer with MCT, concluded that the already published preclinical and clinical data “is 
robust enough to recommend considering this kind of therapy as a treatment option in patients 
with MBC” [106]. In our opinion we should follow this recommendation and, at the same time, 
continue developing the clinical protocols that will provide all the lacking information about 
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Figure 1. Mechanisms responsible for the therapeutic effect of Metronomic Chemotherapy 
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TUMOR/CELLS TREATMENTS § MAIN FINDINGS REF. 
 
BALB/cJ  EMT-6/CTX  CY: Bolus dose 150mg/kg every 3 or 
6 weeks, plus 20mg/kg/d in drinking 
water 
Antitumor effect, Mild toxicity 
Reduction of CEPs 
39 

















CY: 20 and 25 mg/kg/day in drinking 
water plus DC101: 800 μg/mouse 
i.p. twice/week. 
Antitumor effect 


















Group 3: VNB: 0,5mg/kg i.p or ADR: 
1mg/kg i.p. or CIS: 1-2mg/kg i.  
Group 4: CYP-A: 10 mg/kg, i.p.  or 
VER: 20 mg/kg, i.p. every 3 days 
Group 5: Group 3 plus Group 4 
Group 6: Group 3 plus DC101: 800 
μg/mouse i.p. every 3 days 
Anti-tumor effect 








CY: 20 mg/kg/d in drinking water 
plus TaRZ: 1 mg/mL i.p. weekly (25 
mg/kg/wk). 
Antitumor effect, Low toxicity 







UFT: 15 mg/kg/d plus CY: 20 
mg/kg/d in drinking water 
Antitumor/Antimetastatic effects  
Antiangiogenic activity  




231/LM2-4 CY: 20mg/kg/day in drinking water 
plus OXI-4503: 50mg/kg i.p. every 
two weeks. 
Antitumor effect 
Diminished microvessel density  
Increase in apoptosis and tumor 
hypoxia   








CY: 20 mg/kg in drinking water plus 
TRZ: 20 mg/kg i.p twice weekly 
Antimetastatic effect  
Prolonged survival 
46 
Balb/cJ  LM2-4 LY2334737, 6mg/kg/day p.o. plus 
CY:  bolus, 100mg/kg i.p. on day 1 
followed by continuous 20mg/kg/d 
in drinking water 
Antitumor effect  
Increase in vessel stability, 
functionality and blood flow 
35 
Balb/c  M-234p  
M-406 
CY: 30 mg/kg/day in drinking water 
plus CEL: 30 mg/kg p.o. five 
times/week 
Antitumor/Antimetastatic effects  
Increase in apoptosis 
Decrease in proliferation and VEGF 
serum concentration 





 Balb/c  M-234p 
M-406 
CY: 30 mg/kg/d in drinking water 
plus DOX: 0.5 mg/kg i.p. three 
times/week 
Prolonged survival 






CY: 20mg/kg/d in drinking water 
plus ultrasound stimulated 
microbubbles 
Antitumor effect  










CY: 20 mg/kg/day in drinking water, 
CAP: 100 mg/kg/day daily p.o. 
Antitumor/Antimetastatic effects 
Decrease in MDSC and Treg cells 
Increase in NK and T cells 
50 
BALB/c EMT-6/P,  
EMT-6DDP  
 GEM: bolus 160 mg/kg every 3 
days, i.p., plus CY: 20mg/kg/d 
  CY: 20mg/kg/d 
 Anti-CTLA-4: 100 μg, day 1 and 35 
μg, day 6 plus CY: 20mg/kg/d 
 Anti-CTLA-4: 100 μg, day 1 and 35 
μg, day 6 first line and then a 
second-line therapy of GEM: 160 
mg/kg, i.p every 3 days 








TVTE: 10 mg/kg/d i.p. plus 
Selenomethionine: 5 mg/kg/d i.p., 
RAP: 5 mg/kg/d i.p. and CY: 10 
mg/kg/d i.p.  
Antitumor/Antimetastatic effects 
Increase in apoptosis  
Decrease in proliferation and hypoxia 
53 
Balb/c  M-234p CY: 20mg/kg/day in drinking water 
plus LOS: 150/200 mg/kg/d in the 
drinking water 
Antitumor/Antimetastatic effects  
Increase in apoptosis  
Decrease in proliferation, CAF and 
collagen production 




4T1  CY: 5 (low dose), 10, 20 (medium 
doses) and 40 (high dose) mg/kg/d, 
plus VIN: 3 (low dose), 6 and 9 
(medium doses) 12 mg/kg (high dose) 
p.o and 5-FU: 5 (low dose), 10–25 
(medium doses), 50 mg/kg (high 
dose) 3 times/week i.p. for 3 weeks 
and Anti-PD-L1 and anti-PD-1: 
0.2 mg/mouse i.p. every 2 days for a 
total of 5 doses.   
Antitumor/Antimetastatic effects 
Modifications of circulating and 





231 MCF-7  
HCC1937 
HCC1954 
DOX/DOCA: 1.25, 2.5, or 5 mg/kg 
p.o. once a day, plus MK-8776: 30 
mg/kg, i.p. once a week. 
Antitumor effect  






231 MCF 7 
line EAC 
Group DoxMG: DOX 3mg/kg plus 
MG 10mg/kg 5 days 
 Group CisMG: CIS 3mg/kg once a 
week plus  MG 10mg/kg-5 days 
Antitumor effect  
 
57 
BALB/c  4T1 cell  CAP: 200 mg/kg o.p. plus 
Ginsenoside Rg3:10 mg/kg/d p.o. 
Antitumor effect, No weight loss 
Microvessels decrease  
Low tumor VEGF expression 
58 
BALB/c TUBO cells PTX: 60 μg plus : HER-2 and VEGF 
peptide mimics: 300 μg  
Antitumor effect 





Sunitinib: 60mg/kg p.o. plus TOP: 
1mg/kg/d p. o. 
Antitumor effect.  
Prolonged survival 
60 
SCID  4T1-luc  Ang2 Ab: 6mg/kg, i.p, or Ab VEGF: 
10mg/kg i.p. twice a week 
Antitumor/Antimetastatic effects 





Inhibition of recruitment of bone 
marrow-derived myeloid cells 
BALB/c 4T1  Camellia sinensis: 0.6 g/kg/d orally 
fed every day plus ZOL: 0.0125 
mg/kg, i.p. twice a week 
Antitumor/Antimetastatic effects  
 Increase in tumor cell death.  






TOP: 1 mg/kg/d p.o. plus 
Pazopanib: 150 mg/kg /d p.o. and 
Sunitinib: 60 mg/kg/d p.o.  
 
Antitumor/Antimetastatic effects 
Decrease in proliferation  
Increase in apoptosis and 
microvascular density 








CV: 1 g/kg, orally fed daily plus ZOL: 
0.0125 mg/kg, i.p. twice a week. 
Antitumor/Antimetastatic effects  







MET: 400 mg/kg/d in drinking water 
plus PROP :7 mg/kg/d in drinking 
water 
Antitumor/Antimetastatic effects 
Increase in apoptosis  





§: not all the experimental group are mentioned; 5-FU: 5- Fluoruracil; ADR: Adriamycin; Ang2 Ab:  anti-angiopoietin-2; CAF:  
tumor associated fibroblasts; CAP: Capecitabine; CEL: Celecoxib; CIS: Cisplatin; CTLA-4: cytotoxic T-lymphocyte–associated 
antigen 4; CV: Coriolus versicolor; CY: Cyclophosphamide; CYP-A: Cyclosporin A; DC101: monoclonal antibody for mouse 
VEGFR-2 (vascular endothelial growth factor receptor 2); DOX: Doxorubicin, DOX/DOCA: complex of DOX plus deoxycholic 
acid; GEM: Gemcitabine; LOS: Losartan; LY2334737: oral prodrug of GEM; MDSC: myeloid-derived suppressor cells; MET: 
Metformin; MG: Methylglyoxal; MK-8776: Chk1 (Checkpoint kinase 1) inhibitor; NK: Natural Killer cells; OXI-4503: vascular 
disrupting agent; PD-1: programmed cell death-1; PD-L1: programmed cell death-1 ligand;  PROP: Propranolol; PTX: 
Paclitaxel; RAP: Rapamycin; TOP: Topotecan; TRaZ: Tirapazamine; Treg: regulatory T cells; TRZ: Trastuzumab; TVTE: Tumor 
Vasculature–Targeted Enzyme; UFT:  4:1 molar combination of uracil and tegafur; VEGF: vascular endothelial growth factor; 
VER: Verapamil; VIN: Vinorelbine; VNB: Vinblastine; ZOL: Zoledronate.   
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II 
(20) 
Arm Her 2+: 
weekly PTX 
and DOX + CY 
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Safety 
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0 7/42 6/42 17
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31% - - PFS: 7±0.18 
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24% 2.5 12 16 patients 
with non-prior 
chemotherapy 
for MBC; no 
significant 
differences in 











0 3/22 9/22 18
%§ 













 51%   
CCR 
(33) 




N/A 0 1/33 17/3
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TZB+CY+MTX N/A 0 4/22 6/22 18
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2/21 3/21 8/21   9.82 12.9
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Most AE were 
reported and 










































































57% 7 16 For RespP OS: 















42% 3.3 9.8 Treatment was 
well tolerated. 








CAP + CY + 















VRB + CAP DLT 5/31 9/31  16
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CY + MA RR, 
Safety 
7/29 2/29 3/29 31
% 
41% 7.4 13.4 The treatment 















77% - 11 
 
























CY+CEL CB, TTP, 
PFS, OS, 
safety 
- 1/15 6/15 7% 46.7
% 
3.5 11 1-year OS: 
46.7%. No 
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There were no 












100 + DTX + 
carboplatin + 
metronomic 













- - - - - 24 29 
 
 
§ calculated with data given by authors; 5-FU: 5-Fluoruracil; AE: hematological adverse events; BEV: 
Bevacizumab; CAP:Capecitabine; CB: clinical benefit;  CEL: Celecoxib; CR:  complete response; CY: 
Cyclophosphamide; D: Deltaparine; DLT: dose-limiting toxicity; DOX: Doxorubicin; DTX: Docetaxel; ECF: 
Epirubicin, Cisplatin, 5-Fluorouracil; ERL: Erlotinib; F: Fulvestrant; FEC-100: 5-Fluorouracil, Epirubicin, 
Cyclophosphamide; LET: Letrozole; MA: Megestrol acetate; MTD: maximum tolerated dose; MTX: Metotrexate;  
N/A: not available;  NHAE: non-hematological adverse events; N-PLD: Non Pegylated Liposomal Doxorubicin; OS 
(mo): overall survival (months); PLD: Pegylated Liposomal Doxorubicin; PFS: progression free survival; PR: partial 
response; PRED: Prednisone; PTX: Paclitaxel; ResP: responder patients; RR: response rate; RT: Radiotherapy; SD: 
stable disease; TTP (mo): time to progression (months); TZB: Trastuzumab; VAN: Vandetanib; VCR: Vincristine; 
VRB: Vinorelbine; WBRT: Whole Brain Radiotherapy 
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